FILE PHOTO: A logo is pictured on the headquarters of the World Health Organization (WHO) ahead of a meeting of the Emergency Committee on the novel coronavirus (2019-nCoV) in Geneva, Switzerland, January 30, 2020. REUTERS/Denis Balibouse
ZURICH (Reuters) - The World Health Organization (WHO) on Tuesday promised a swift review of data on hydroxychloroquine, probably by mid-June, after safety concerns prompted the group to suspend the malaria drug's use in a large trial on COVID-19 patients.
U.S. President Donald Trump and others have pushed hydroxychloroquine as a coronavirus treatment, but the WHO on Monday called time after the British journal The Lancet reported patients getting hydroxychloroquine had increased death rates and irregular heartbeats.
